Regeneron to stop enrolling very sick COVID-19 patients in antibody trials

FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermidNEW YORK: Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalised patients, based on the recommendation of an independent safety board.

The recommendation was based on a potential safety signal and an unfavourable risk-benefit profile at this time, the company said. Rival Eli Lilly & Co stopped enrolling such patients based on a similar suggestion earlier this week.The drugmaker said on Wednesday the treatment lowers virus loads in some non-hospitalised patients. US President Donald Trump received the treatment early in his illness, before he was hospitalised, and has credited it for his recovery from COVID-19.

The drugmaker said it would inform the US Food and Drug Administration, which is evaluating the treatment for a potential emergency use authorisation in mild-to-moderate patients at high risk for poor outcome.President Trump had said he would push for an EUA for it and make it free to Americans.Regeneron said it remains blinded to the data - meaning it does not know which patients have received the drug and which have not - and is implementing the recommendations.

The antibody cocktail is being studied in four ongoing late-stage clinical trials, including two studies in hospitalised and non-hospitalised COVID-19 patient.

Then what is the use? Another Nincompoop treatment?

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Regeneron Covid-19 therapy reduces viral load, need for carePatients who had the highest viral levels, or produced the lowest levels of antibodies themselves, were most likely to respond to treatment.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

Japan's Shionogi readies COVID-19 vaccine for December trial: CEOShionogi & Co is planning clinical trials by year-end for what may be one of Japan's first domestically produced COVID-19 vaccines to reach the ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Japan's Shionogi readies Covid-19 vaccine for December trialThe company plans to put its vaccine candidate into Phase 1 clinical trials in December and shift into Phase 2 by January.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

Australia's COVID-19 hotspot state reports one case after four-month city lockdown liftedAustralia's COVID-19 hotspot state Victoria reported only one new infection on Thursday, a day after it lifted a four month lockdown in the city ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Asia's Covid-19 control tempers global stock selloff, US futures jumpSINGAPORE (REUTERS) - Asian stock markets fell on Thursday (Oct 29) but not as sharply as Wall Street's rout overnight, while oil bounced off lows and US futures jumped, as Asia's brighter economic outlook offset investor worries about fresh COVID-19 lockdowns in Europe.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

Baseball: Los Angeles Dodgers star Turner ignored Covid-19 safety protocols, says MLBThe third baseman was withdrawn during Game Six after he tested positive.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »